Opinion

Video

Unmet Needs and Clinical Considerations for HER2+ NSCLC

Key Takeaways

  • Effective therapies that penetrate the blood-brain barrier and target resistant tumor cells are needed in lung cancer brain metastases management.
  • Current treatments often provide limited survival benefits and significant side effects, highlighting the need for improved therapeutic options.
SHOW MORE

Panelists discuss how persistent unmet needs in HER2-directed therapy for NSCLC present opportunities for future research and pipeline therapies, potentially addressing challenges such as treatment resistance, improved efficacy, or reduced toxicity profiles.

Video content above is prompted by the following:

  • What unmet needs persist in this space and what opportunities exist for future research or pipeline therapies?
Related Videos
Screenshot of an interview with Ruben Mesa, MD
Justin Oldham, MD, MS, an expert on IPF
Ruben Mesa, MD
Amit Garg, MD, Northwell Health
4 KOLs are featured in this series
4 KOLs are featured in this series
Surbhi Sidana, MD, MBBS
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo